Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) on Thursday announced the launch of Prucalopride Tablets, a generic version of Motegrity.
The US Food and Drug Administration (FDA) has granted ANI 180-day marketing exclusivity for its Prucalopride Tablets.
This launch follows the FDA's approval of ANI's Abbreviated New Drug Application (ANDA).
ANI's Prucalopride Tablets are expected to compete in a market with approximately USD168m in annual sales.
Nuvation Bio secures NMPA approval for taletrectinib in China
European Commission approves Evkeeza for children with HoFH aged 6 months and older
Oculis reports positive Phase 2 results for OCS-05 in acute optic neuritis
LPOXY Therapeutics acquires Xeno Biosciences' key assets
Eton Pharmaceuticals acquires Galzin to expand rare disease treatments
Fapon Biopharma introduces FP008 immunotherapy for refractory cancers at Biotech Showcase
ANI Pharmaceuticals launches generic Motegrity tablets
MicuRx's MRX-5 receives US FDA Orphan Drug Designation to treat NTM infections
Kazia Therapeutics updates on paxalisib regulatory pathway after FDA meeting
FDA approve Opdivo Qvantig with ENHANZE for subcutaneous use